Sadia Zafar

Sadia Zafar

Auto-generated profile, based on publicly available information

Sadia Zafar

Residency Program, Bahcesehir University School of Medicine, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
SESuheyla Ekemen
Suheyla Ekemen
EBEbru Bilir
Ebru Bilir
HSHagar Elsayed Akram Soultan
Hagar Elsayed Akram Soultan
SZSadia Zafar
Sadia Zafar
FDFigen Demir
Figen Demir
CCCevayir Coban
Cevayir Coban
Purpose: Breast cancers exhibit molecular heterogeneity, leading to diverse clinical outcomes and therapeutic responses. Immune checkpoint inhibitors targeting PD-L1 have shown promise in various malignancies, including breast cancer. Lipocalin 2 (LCN2) has also been associated with tumor aggressiveness and prognostic potential in breast cancers. However, the expression of PD-L1 and LCN2 in breast cancer subtypes and their prognostic implications remains poorly investigated. Methods: A retrospective analysis of 89 primary breast cancer cases was conducted to assess PD-L1 and LCN2 expressions using immunohistochemistry. Cases were classified into four different molecular subtypes based on ER, PR, HER2, and Ki-67 status. Associations between PD-L1 and LCN2 expressions and various prognostic factors were examined. Results: Although low expression of LCN2 (Allred score of < 3) was observed even in normal breast tissue, LCN2 expression with increasing Allred score (≥ 3) positively correlated with the histological grade, high Ki-67 proliferation index, and ER/PR negativity. Significant elevations of LCN2 and PD-L1 expressions were observed in triple-negative and HER2-positive breast cancers. Conclusion: The results of the study highlight the association of LCN2 with known prognostic factors and molecular subtypes. To identify potential immunotherapy recipients, it would be useful to evaluate LCN2 as well as PD-L1 immune targets in different subgroups of breast cancer patients. Further studies with larger patient numbers are warranted to validate these observations and establish standardized scoring criteria for LCN2 expression assessment.